Thursday, October 6, 2022
News
NEWS HOME
»
PRN INDIA
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
  SocialTwist Tell-a-Friend  
   

  • Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer
  • Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall study population and patients whose tumors harbor an ESR1 mutation
  • U.S. FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of February 17, 2023

FLORENCE, Italy and NEW YORK, NY, Aug. 11, 2022 /PRNewswire/ -- The Menarini Group ("Menarini"), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.

The FDA grants Priority Review designation to medicines that it considers have the potential to provide significant improvements over current SOC in the safety and effectiveness of the treatment, diagnosis, or prevention of serious conditions. The FDA granted Fast Track designation for elacestrant in 2018.

"The FDA's acceptance of our NDA with Priority Review marks an important regulatory milestone  for our company," commented Elcin Barker Ergun, Chief Executive Officer of the Menarini Group. "We look forward to working with the FDA during its review of this submission, which addresses a new potential therapeutic option for a major unmet need in the management of patients with advanced or metastatic breast cancer after resistance builds in the earlier lines of the treatment."

The NDA submission was supported by results of the Phase 3 data from the EMERALD study. EMERALD met both of its pre-specified primary endpoints of progression-free survival (PFS) in the overall population and in patients with the ESR1 mutation (mESR1) compared to SOC endocrine monotherapy; the trial's comparator arms were investigators' choice of either fulvestrant or an aromatase inhibitor. The PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in the ESR1 mutation population. The clinical trial data showed that elacestrant reduced the risk of disease progression or death by 30% in all patients and by 45% in patients with ESR1 mutation. The data also showed a manageable safety profile.

Elacestrant is an investigational compound and is not approved by any regulatory authorities. The Marketing Authorization Application (MAA) has also been submitted to European Medicines Agency (EMA) in July 2022. More information about clinical trials with elacestrant is available at www.clinicaltrials.gov.

The Menarini Group obtained global licensing rights for elacestrant in July 2020 from Radius Health, Inc (NASDAQ: RDUS), who conducted and successfully completed the EMERALD study. Based on the positive phase 3 data, Stemline, with the support of Radius, submitted a New Drug Application (NDA) in June 2022 to the FDA. The Menarini Group is now fully responsible for global registration, commercialization and further development activities for elacestrant. Stemline, headquartered in New York City, will commercialize elacestrant if approved by the FDA. Stemline is focused on bringing transformational oncology treatments to cancer patients, and currently commercializes a novel targeted treatment for patients with blastic plasmacytoid dendritic cell neoplasm in both the United States and Europe.

About Elacestrant (RAD1901) and the EMERALD Phase 3 Study

Elacestrant is an investigational selective estrogen receptor degrader (SERD), which is being evaluated for potential use as a once-daily oral treatment in patients with ER+/ HER2- advanced or metastatic breast cancer. In 2018, elacestrant received Fast Track designation from the FDA. Preclinical studies completed prior to EMERALD indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients. The study enrolled 477 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK 4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator's choice of an approved hormonal agent. The primary endpoint of the study was progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. Secondary endpoints included evaluation of overall survival (OS), objective response rate (ORR), and duration of response (DOR).

About The Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com.

About Radius

Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology. Radius' lead product, TYMLOS ® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms.

Logo: https://mma.prnewswire.com/media/1876570/MENARINI_GROUP.jpg

More News by PR Newswire India

World Agricultural Center Opens in Harbin, China

ICANN Board Elects New Leadership

Archer Aviation Applauded by Frost & Sullivan for Enabling Easier Intercity Travel with Its Urban Air Mobility Solutions

Titan.ium Platform's Portfolio Provides a Value-Added Customer Defined Applications (CDA) Product Suite

HABANOS, S.A. PRESENTED QUAI D'ORSAY IMPERIALES TRAVEL HUMIDOR AT THE TFWA INTERNATIONAL FAIR IN CANNES

New Torch and Grit Test Method by UL Solutions Offers a Standardized Approach to Screen Electric Vehicle Battery Enclosure Materials

Sumsub launches 1-click - document-free verification for over 2 billion users

Navisite Expands 'Next Steminist' Scholarship Program to India

IGU 2022 Global Wholesale Gas Price Survey Report

Survey commissioned by IHG Hotels & Resorts reveals what consumers value when they travel

lowRISC Appoints Cybersecurity Expert Prof. Dr. Claudia Eckert to Board of Directors

Brazilian Connected Trucks Telematics will Reach 2.59 Million Units by 2027

JACK&JONES, VERO MODA & ONLY launch their newly re-vamped flagship store on Linking Road, Mumbai

Cancer Can Be Treated! OncoDynamiX Launches Cancer treatment solutions to South Asia, Africa, and Latin American countries

Teachers Have the Power to Transform Lives

AG&P Group Appoints Sandeep Mahawar as Chief Commercial Officer of LNG Terminals and Logistics

Tejas Networks wins "Best Made in India Telecom Innovation award" at India Mobile Congress (IMC)

Bloom IVF Group rolls out Artificial Intelligence across its clinics in India, helping patients get pregnant sooner and for lower cost

INFANTINO AND BECKHAM HAIL ASPIRE ACADEMY AS INTEGRAL TO QATAR'S WORLD CUP LEGACY AS GLOBAL SUMMIT 2022 ENDS

Celigo Opens APAC Headquarters Amid Record Growth in Region

PARADISO, BARCELONA IS NO.1 AS THE WORLD'S 50 BEST BARS 2022 ARE REVEALED

infodas receives NITES certification from the Cyber Security Agency of Singapore

Automation Anywhere and the Center for Humanitarian Technology Launch 'Telegram for Humanity' Bot to Aid Refugees in Ukraine

Pomerantz Law Firm Opens London Office

Sphera Completes Previously Announced Acquisition of riskmethods, a Leader in Artificial Intelligence Supply Chain Risk Management Software

Hard Rock International Celebrates 23rd Annual PINKTOBER Campaign by Partnering with World-Renowned Chef Dominique Crenn

World's Fastest Growing Staking Service Provider Born out of Lugano, Switzerland

Firmenich Annual General Meeting 2022

Unispace: Data reveals Gen Z rely on the traditional office more than any other generation

Information Office of Beijing Municipal Government' Features: "My Beijing, My Story" Depicts the Lifestyle of People Living in Beijing

Automation Anywhere Unveils the Automation Success Platform with a Surge of Innovations

Deloitte Named a Leader in Worldwide Industry Cloud Professional Services by the IDC MarketScape

HAVAS HEALTH & YOU APPOINTS PAUL PFLEIDERER AS PRESIDENT OF HAVAS LIFE NEW YORK

Solace Launches Event Portal 2.0, Addressing the Biggest Challenges Enterprises Face in Designing, Managing and Governing Event-Driven Architecture at Scale

IMG Appoints Amanda Winkle as Chief Operating Officer

Vinco Ventures Announces Ross Miller as CEO and Settlement of Litigation

RevitaLash® Cosmetics Champions Breast Cancer Awareness, Research, and Support Worldwide with 2022 Pink Program Announcement

Aspire Academy and FIFA Kick Off the 8th Global Summit with high profile FIFA guests David Beckham and Wenger

EvolveWare Facilitates Non-disruptive Application Modernization with Industry's First and Only Agile Business Rules Extraction Solution

Stamus Networks Signs Reseller Agreement with EliteVAD

China Matters' Feature: How Does Basketball Shape Dongguan's Sports Culture?

Altair Presents Open, Flexible, and Scalable Total Digital Twin Solution

IZUMA NETWORKS ACQUIRES PELION'S DEVICE MANAGEMENT BUSINESS

Globalization Partners Rebrands as G-P and Reaffirms its Promise to Make a Global Workforce Possible for Growing Companies

Secureworks State of the Threat Report 2022: 52% of ransomware incidents over the past year started with compromise of unpatched remote services

First-of-its-kind government-industry partnership announced between Deakin University, Australia and Ministry of Education and Ministry of Skill Development and Entrepreneurship, Government of India

LyondellBasell Catalyst Production Expansion Adds Life to Infrastructure Projects

BE EVERYTHING - A new chapter opens in the story of United Colors of Benetton: new creative director, Andrea Incontri presents his first fashion show

PwC announces record global revenues of US$50 billion

Challenge the Highest Level of <MIR4>! A New Content, Hell Raid, Unveiled

Leading Gaming technology provider Quixant announces the launch of new cabinet offering

StoreHippo® launches Mystore Buyer and Seller Apps for ONDC

Cambrex Announces Stability Storage Expansions in Ireland and Belgium

TimesPro collaborates with IMT Hyderabad to launch programmes in Business & Retail Management

Industrial Transformation ASIA-PACIFIC 2022 returns to catalyse sustainable growth for advanced manufacturing in the region

The PI Group and Averna Announce their Partnership

Academic partnerships in focus, Global Education Summit commences at Chandigarh University

UST and Mendix Collaborate to Accelerate Low Code Development in Spain

Nestlé launches NESCAFÉ Plan 2030 to help drive regenerative agriculture, reduce greenhouse gas emissions and improve farmers' livelihoods

Ingenico Launches as Independent Company Following Acquisition by Apollo Private Equity Funds

Stockify announces single-window online service to buy unlisted equities

Manipal Hospital Whitefield's Exclusive Take on Minimally Invasive Advanced Surgical Procedures (MIAS)

THE LEELA PALACES, HOTELS AND RESORTS PARTNERS WITH RAJASTHAN POLO CLUB FOR ITS INAUGURAL SPONSORSHIP OF THE ROYAL SPORT IN INDIA

CLO Virtual Fashion Announces the Acquisition of GoVise Technologies

Education Cannot Wait Announces US$11.8 Million Catalytic Grant in Haiti

DXC Technology Calls for Latest Innovations from Insurance Startups and Scaleups across Asia Pacific through the DXC Invitational

Global AdTech Company TripleLift Names Dave Clark as New Chief Executive Officer

Navneeth Sulakhe joins Innoviti as Senior VP Human Resource Management

KEI Wires & Cables Hosts Real Kabbadi League Season 2

Automation Anywhere Secures $200 Million in Financing from Silicon Valley Bank and Hercules Capital

2022 World Trade Centers Association Member Forum Returns to New York City for First Time in Two Years

TATA POWER REINFORCES COMMITMENT TOWARDS GREEN ECOSYSTEM CONSERVATION ACROSS ITS RENEWABLE SITES

Azure Power wins the prestigious Golden Peacock Award for Sustainability

FANDOM ACQUIRES LEADING ENTERTAINMENT & GAMING BRANDS INCLUDING GAMESPOT, TV GUIDE AND METACRITIC

National Engineering Industries Ltd (NBC Bearings) honored with 'Iconic Brands of India 2022'

Celebrating Glorious 35 Years of BIMTECH

HABANOS, S.A. PRESENTED THE MONTECRISTO WIDE EDMUNDO IN WORLD PREMIERE IN SPAIN

Sanjay Ghodawat Foundation awarded The Mahatma Award 2022

STL announces Gram Galaxy - India's first integrated solution to connect villages with fibre

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Healthium Medtech amongst the first in Asia and first Indian Medtech Company to receive CE certification under the EU MDR (European Union Medical Device Regulation) norms for Class III implants

Jagadguru Kripalu Parishat holds Grand Rath Yatra on 3rd October 2022 near Kunda, Pratapgarh in honor of the 100th Birth Anniversary of Jagadguru Shri Kripalu Ji Maharaj

Addteq APAC Announces Rebranding, Changes Name to Enreap

Karwa Chauth 2022: FlowerAura Is All Geared Up To Enhance The Celebrations

DMCC AWARDED GLOBAL FREE ZONE OF THE YEAR FOR EIGHTH CONSECUTIVE YEAR

New Book Property Tax in Asia Provides the First Comprehensive Analysis of the Property Tax Across the World's Largest Continent

UN WOMEN'S HeForShe EXPANDS MOVEMENT THROUGH KEY PUBLIC AND PRIVATE PARTNERSHIPS IN EAST ASIA

STL unveils 5G cosmos to help Indian telcos fiberise their networks for 5G

STL launches Multiverse - India's first Multicore fibre and cable; aims to revolutionize the optical landscape

Tejas Networks successfully demonstrates end-to-end network based on its indigenous 4G/5G wireless, optical and satellite products

IIIT Hyderabad and Silicon Labs Launch Campus-wide Wi-SUN Network for Smart City Applications

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
One pilot killed, another injured as Arm...
Assam: BJP cadres miffed with reports of...
Fake job racket: MEA rescued 45 trapped ...
CDSCO takes up urgent investigation on W...
7 dead, several feared missed after flas...
R'than minister compares Sachin Pilot wi...
More...    
 
 Top Stories
Sai Praneeth to clash with Mithun i... 
Assam: BJP cadres miffed with repor... 
Hardeep Puri to lead business deleg... 
Indian Super League to kick off on ... 
Fake job racket: MEA rescued 45 tra... 
Khattar visits Medanta Hospital, in... 
CDSCO takes up urgent investigation... 
Ayushmann Khurran, Tabu's crime thr...